Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 30,000 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $50.45, for a total transaction of $1,513,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Harold Bernstein also recently made the following trade(s):

• On Monday, February 2nd, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $46.02, for a total transaction of $690,300.00.
• On Wednesday, January 7th, Harold Bernstein sold 25,156 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.20, for a total transaction of $1,011,271.20.
• On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.00, for a total transaction of $16,480.00.
• On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.43, for a total transaction of $179,185.76.
• On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.56, for a total value of $1,825,200.00.

Maze Therapeutics Stock Performance

NASDAQ MAZE traded up $1.39 on Thursday, hitting $51.83. 703,513 shares of the stock traded hands, compared to its average volume of 460,240. The business’s fifty day moving average is $44.40 and its two-hundred day moving average is $35.22. Maze Therapeutics, Inc. has a 12 month low of $6.71 and a 12 month high of $52.57. The firm has a market capitalization of $2.49 billion, a price-to-earnings ratio of -2.48 and a beta of 4.47.

Analysts Set New Price Targets

Several research firms have recently weighed in on MAZE. HC Wainwright reiterated a “buy” rating on shares of Maze Therapeutics in a research note on Wednesday, January 28th. Wells Fargo & Company began coverage on Maze Therapeutics in a research note on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price objective on the stock. Raymond James Financial started coverage on shares of Maze Therapeutics in a report on Thursday, November 13th. They set an “outperform” rating and a $48.00 price objective on the stock. BTIG Research reiterated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Monday. Finally, Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.63.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MAZE. Janus Henderson Group PLC grew its position in shares of Maze Therapeutics by 318.0% during the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock valued at $130,197,000 after purchasing an additional 2,390,713 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Maze Therapeutics by 218.1% in the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock worth $34,615,000 after buying an additional 915,342 shares in the last quarter. Marshall Wace LLP boosted its stake in Maze Therapeutics by 3,868.5% during the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after buying an additional 758,104 shares during the period. Caligan Partners LP purchased a new position in Maze Therapeutics during the fourth quarter worth about $22,794,000. Finally, ArrowMark Colorado Holdings LLC purchased a new position in Maze Therapeutics during the third quarter worth about $14,135,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.